Two brand names consistently come up in the conversation around glucagon-like peptide-1 receptor agonists (GLP-1 RAs): Ozempic^® and Wegovy^®. While both drugs share the same active ingredient (semaglutide), the FDA approves them for different health conditions.

To settle the Ozempic^® versus Wegovy^® debate, this guide breaks down their real-world results, common side effects, and eligibility rules. Read on to discover how these medications compare and learn which one might be right for you.

What are Ozempic^® and Wegovy^®?

Pharmaceutical company Novo Nordisk manufactures both Ozempic^® and Wegovy^®. The company packages the identical active ingredient, semaglutide, under separate brand names to meet strict regulatory guidelines: Ozempic^® manages type 2 diabetes, while Wegovy^® treats chronic obesity.

How semaglutide works

Semaglutide mimics GLP-1, a natural hormone your body produces to manage digestion and blood sugar. The medication works through several biological processes: 

• Regulating insulin: Semaglutide stimulates the pancreas to release insulin the moment you eat. This response helps your cells open up to absorb sugar immediately, converting glucose into instant fuel rather than letting it pool in your bloodstream.
• Suppressing glucagon: Your liver relies on a hormone called glucagon to release stored glucose into your blood stream. Normally, your body triggers this release when it thinks you’re fasting and need an energy boost. By suppressing this hormone, semaglutide prevents unwanted blood sugar spikes.
• Delaying gastric emptying: Semaglutide slows down how quickly food leaves your stomach. This extended digestion keeps you feeling fuller for longer. 
• Stabilizing appetite: The medication directly targets the hunger centers in your brain, significantly reducing your daily cravings. 

While natural GLP-1 carries these same benefits, your body breaks it down in about two minutes. By contrast, semaglutide stays in your system for about one week. This extended duration allows a single weekly injection of either Ozempic^® or Wegovy^® to provide continuous effects.

What are Ozempic^® and Wegovy^® approved for? 

Here’s a comparison of how these two brands diverge in their clinical uses, delivery methods, and typical out-of-pocket costs:

The dosing difference between Ozempic^® and Wegovy^®

Aside from their different FDA approvals, the main difference between Ozempic^® and Wegovy^® is dosing. 

Because managing chronic obesity requires a higher dose than regulating type 2 diabetes, maintenance doses for Wegovy^® trend significantly higher than those for Ozempic^®. While these higher strengths deliver greater weight loss, they also increase the likelihood and intensity of side effects like nausea and vomiting.

Furthermore, both medications now come in both injectable and oral pill forms. If you compare the doses, you’ll notice oral tablets require daily administration at higher milligram strengths than weekly injections. This is because your body absorbs roughly 89% of an injection into the bloodstream, but it absorbs less than 1% of an oral tablet through the digestive tract. 

Here’s how these maximum doses compare:

• Injectable Ozempic’s^® maximum dose is 2 mg, while the maximum oral dose is 9 mg.
• Injectable Wegovy’s^® maximum dose is 7.2 mg, but manufacturers typically recommend a 2.4 mg target. The maximum oral dose is 25 mg.

What’s better for weight loss, Ozempic^® or Wegovy^®?

Because Wegovy^® features higher maximum doses of semaglutide, it triggers more substantial weight reduction than Ozempic^®. Furthermore, the FDA explicitly approved Wegovy^® for chronic weight management, whereas Ozempic^® only supports weight loss as an off-label benefit.

To test this, Novo Nordisk conducted a clinical trial (the STEP 2 study) published in The Lancet. Researchers compared a 1 mg dose of semaglutide (a common Ozempic^® dose) against a 2.4 mg dose (the standard Wegovy^® dose) in adults over a 68-week period. 

The study confirmed that Wegovy’s^® higher dose produced greater weight loss outcomes:

• Average weight loss: Patients on the 2.4 mg Wegovy^® dose lost 9.6% of their starting body weight, while those on the 1 mg Ozempic^® dose lost 7%. 
• Overall reduction: Nearly half (45%) of the Wegovy^® group achieved a 10% or greater weight reduction, compared to just 28.7% of the Ozempic^® group. 

While Wegovy^® is the clear winner for weight reduction, the trial also highlights why doctors often prescribe Ozempic^® off-label for weight loss. Even at lower diabetes-focused strengths, semaglutide consistently reduces body weight. 

Ozempic^® vs. Wegovy^®: Side effects

Because Ozempic^® and Wegovy^® share the same active ingredient, they also share an identical list of common side effects. These primarily affect your digestive tract as your body adjusts to the medication. 

Clinical trials highlight that standard therapeutic doses of Wegovy^® carry a higher rate of these symptoms than Ozempic^® because it features a higher concentration of semaglutide (0.5 mg to 1 mg for Ozempic^® versus the maximum 2.4 mg for Wegovy^®):

Fortunately, these symptoms are typically short-lived. Most patients report that side effects peak during the first few weeks or immediately after a dose increase, then fade quickly. Scaling your dosage up slowly alongside your doctor will help keep these symptoms manageable.

Important safety note: Doctors advise against using either medication if you’re pregnant, planning to conceive, or currently breastfeeding.

Who’s eligible for Ozempic^® vs. Wegovy^®?

Your doctor will determine your eligibility based on your body mass index (BMI), health goals, and existing medical conditions. 

Wegovy^® eligibility criteria

The FDA approves Wegovy^® specifically for chronic weight management. You may qualify for a prescription if you meet one of the following criteria:

• Adult with obesity: A BMI of 30 or higher
• Overweight adult with health risks: A BMI of 27 or higher, plus at least one weight-related condition like high blood pressure or type 2 diabetes
• Adolescents (ages 12+): A BMI at or above the 95th percentile for your age and sex

Ozempic^® eligibility criteria

Doctors prescribe Ozempic^® to manage cardiovascular and metabolic health. To qualify, you must be an adult living with type 2 diabetes who also requires:

• Glycemic control: Semaglutide improves blood sugar management alongside routine diet and exercise.
• Cardiovascular protection: The drug actively reduces the risk of major adverse cardiovascular events (MACE) like stroke and heart attack if you have established heart disease. 
• Renal support: The medication slows down the progression of chronic kidney disease (CKD) damage.

Explore comprehensive GLP-1 care with Maven Clinic

Choosing between Ozempic^® and Wegovy^® is only the first step in your metabolic health journey. Sustaining health improvements like stabilized blood sugar, reduced heart attack risk, and weight loss requires a dedicated support system.

At Maven Clinic, GLP-1 care extends beyond the prescription. Our care team spans over 30 medical specialties, giving you continuous access to endocrinologists, nutritionists, and mental health specialists. We focus on the complete picture to help you achieve lasting wellness. 

That’s why millions of women trust us with their care. Connect with a Maven Clinic specialist today to build your personalized health plan.

FAQ

Can I switch from Ozempic^® to Wegovy^®?

Yes. Because both brands share the same active ingredient, doctors can transition patients between them. However, you should only switch under medical supervision.

Which semaglutide medication is best for weight loss? 

Doctors typically prescribe Wegovy^® because the FDA explicitly approves it for weight loss. While clinicians may prescribe Ozempic^® off-label for this purpose, the FDA limits its official approvals to type 2 diabetes and cardiovascular risk reduction.

Do Ozempic^® and Wegovy^® have the same dosing schedule?

No. Both brands use a four-week escalation schedule to minimize digestive side effects, but their specific milligram milestones differ:

• Ozempic^® injection: Starts at 0.25 mg weekly, increasing every four weeks through 0.5 mg and 1 mg to a maximum dose of 2 mg. 
• Wegovy^® injection: Steps up every four weeks (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) to reach the standard 2.4 mg maintenance dose. If weight loss plateaus, physicians can scale up to a maximum of 7.2 mg weekly.
• Oral tablet formulations: Feature separate dosing scales, stepping up over four-week intervals to a maximum of 9 mg daily for Ozempic^® and 25 mg daily for Wegovy^®.

Does insurance cover Wegovy^® if I already have type 2 diabetes?

Potentially, though coverage depends on your insurance provider and plan details. Commercial health plans typically restrict Wegovy^® coverage to weight management diagnoses, but some insurers approve coverage if you present documented type 2 diabetes alongside specific cardiac risk factors. The clinical care team at Maven Clinic can help verify your benefits and navigate your authorization options.